• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma.

作者信息

Virgen Cesar A, Nguyen Tuyet A, Di Raimondo Cosimo, Amini Arya, Margolin Kim A, Parekh Vishwas, Abdulla Farah R, Modi Badri

机构信息

Department of Dermatology, University of California-Irvine, Irvine, Los Angeles.

Department of Dermatology, Kaiser Permanente-Los Angeles Medical Center, Duarte, California.

出版信息

JAAD Case Rep. 2020 Feb 19;6(3):195-197. doi: 10.1016/j.jdcr.2020.01.008. eCollection 2020 Mar.

DOI:10.1016/j.jdcr.2020.01.008
PMID:32149176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7033293/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/1ea3940d074b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/61d6c54eed64/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/3c034e0258d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/9d15ed2c8cda/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/1ea3940d074b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/61d6c54eed64/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/3c034e0258d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/9d15ed2c8cda/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/917c/7033293/1ea3940d074b/gr4.jpg

相似文献

1
Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma.局部晚期皮肤鳞状细胞癌患者中与西米普利单抗治疗相关的大疱性类天疱疮。
JAAD Case Rep. 2020 Feb 19;6(3):195-197. doi: 10.1016/j.jdcr.2020.01.008. eCollection 2020 Mar.
2
Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.西米普利单抗治疗晚期皮肤鳞状细胞癌：合适的患者选择与展望
Clin Cosmet Investig Dermatol. 2023 Aug 9;16:2135-2142. doi: 10.2147/CCID.S381471. eCollection 2023.
3
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab.在转移性皮肤鳞状细胞癌对西米普利单抗程序性细胞死亡蛋白1阻断完全缓解期间，同时发生高分期皮肤鳞状细胞癌。
JAAD Case Rep. 2021 Oct 20;18:23-25. doi: 10.1016/j.jdcr.2021.10.009. eCollection 2021 Dec.
4
Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report.接受西普单抗治疗局部晚期皮肤鳞状细胞癌后出现口腔溃疡和淋巴结类肉瘤样反应：一例报告。
Einstein (Sao Paulo). 2022 Mar 7;20:eRC6367. doi: 10.31744/einstein_journal/2022RC6367. eCollection 2022.
5
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.慢性化脓性汗腺炎并发高级别鳞状细胞癌，使用西米普利单抗成功治疗：一例报告
Case Rep Dermatol. 2023 Feb 14;15(1):35-39. doi: 10.1159/000525347. eCollection 2023 Jan-Dec.
6
Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma.程序性细胞死亡蛋白1抑制与放射治疗同时进行可使晚期皮肤鳞状细胞癌完全缓解。
JAAD Case Rep. 2019 Aug 29;5(9):763-766. doi: 10.1016/j.jdcr.2019.06.026. eCollection 2019 Sep.
7
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.西米普利单抗用于治疗晚期皮肤鳞状细胞癌。
Drugs Today (Barc). 2019 Aug;55(8):485-494. doi: 10.1358/dot.2019.55.8.3005176.
8
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.西妥昔单抗-rwlc 作为晚期皮肤鳞状细胞癌的一线且唯一治疗药物。
Expert Rev Clin Pharmacol. 2019 Oct;12(10):947-951. doi: 10.1080/17512433.2019.1665026. Epub 2019 Sep 19.
9
[Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].[西米普利单抗治疗局部晚期和转移性皮肤鳞状细胞癌]
Rev Med Liege. 2019 Jul;74(7-8):436-440.
10
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.黏膜类天疱疮、大疱性类天疱疮与抗程序性死亡蛋白1/程序性死亡配体1：1例老年女性在帕博利珠单抗治疗转移性黑色素瘤后发生黏膜类天疱疮的病例报告及文献复习
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.

引用本文的文献

1
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.癌症治疗的皮肤反应及其他未得到充分重视的皮肤科副作用
Curr Treat Options Oncol. 2025 Aug 14. doi: 10.1007/s11864-025-01333-5.
2
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.生物制剂在治疗免疫检查点抑制剂相关皮肤免疫相关不良事件中的应用：病例报告综述。
Am J Clin Dermatol. 2024 Jul;25(4):595-607. doi: 10.1007/s40257-024-00866-z. Epub 2024 May 20.
3
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.

本文引用的文献

1
Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients.利妥昔单抗治疗大疱性类天疱疮患者：20 例患者的回顾性研究。
J Am Acad Dermatol. 2019 Jul;81(1):179-186. doi: 10.1016/j.jaad.2019.03.049. Epub 2019 Mar 25.
2
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.靶向治疗和免疫治疗的皮肤、口腔黏膜、头发和指甲毒性副作用。
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3.
3
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
使用多国多机构皮肤免疫相关不良反应和管理登记处来检测新型疗法。
Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19.
4
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.
5
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.接受免疫检查点抑制剂治疗的患者及银屑病患者中的大疱性类天疱疮——聚焦于临床和组织病理学变异
Dermatopathology (Basel). 2022 Mar 18;9(1):60-81. doi: 10.3390/dermatopathology9010010.
6
Self-resolving bullous pemphigoid induced by cemiplimab.西米普利单抗诱导的自限性大疱性类天疱疮
Dermatol Ther. 2022 Jun;35(6):e15466. doi: 10.1111/dth.15466. Epub 2022 Mar 29.
7
Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.新型靶向治疗药物的皮肤不良反应——免疫检查点抑制剂和 EGFR 抑制剂。
J Dtsch Dermatol Ges. 2021 Nov;19(11):1621-1643. doi: 10.1111/ddg.14641.
8
Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.病例报告：接受西米普利单抗治疗的多灶性局部晚期皮肤鳞状细胞癌患者并发自身免疫性寻常型天疱疮
Front Oncol. 2021 Aug 23;11:691980. doi: 10.3389/fonc.2021.691980. eCollection 2021.
抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.
4
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.西妥昔单抗联合 PD-1 抑制剂治疗晚期皮肤鳞状细胞癌的疗效和安全性
N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.
5
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.利妥昔单抗治疗纳武单抗诱导的大疱性类天疱疮。
JAMA Dermatol. 2017 Jun 1;153(6):603-605. doi: 10.1001/jamadermatol.2017.0091.
6
Development of bullous pemphigoid during nivolumab therapy.纳武单抗治疗期间大疱性类天疱疮的发生
JAAD Case Rep. 2016 Dec 3;2(6):442-444. doi: 10.1016/j.jdcr.2016.05.009. eCollection 2016 Nov.
7
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.靶向 PD-1 和 PD-L1 的免疫检查点抑制剂相关的自身免疫性大疱性皮肤病。
Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.
8
Toxicities of Immunotherapy for the Practitioner.从业者的免疫治疗毒性
J Clin Oncol. 2015 Jun 20;33(18):2092-9. doi: 10.1200/JCO.2014.60.0379. Epub 2015 Apr 27.